CASTRATION-RESISTANT PROSTATE CANCER: NEW PERSPECTIVES IN PHARMACOLOGICAL TREATMENT

Abstract

Prostate cancer remains one of the most actual problems in oncourology due to its high prevalence and resistance to therapy. Within 5 years of active treatment and follow-up, the castration-resistant prostate cancer (CRPC) develops in 10-20% of patients. This type of disease course resists treatments and leads to death. Medical resources distinguish two different forms of CRPC: non-metastatic and metastatic. Such separation is critically important because each of two forms requires different treatment algorithms. This paper summarizes the main outlines of foreign clinical guidelines and reviews the new treatment options for non-metastatic and metastatic CRPC as wells as the design and results of key clinical trials on drug efficiency. To prepare the review, the comprehensive literature search was conducted using PubMed/Medline, the Cochrane Library, EMBASE, CyberLeninka, e-library databases. The search line included phrases containing the following words: prostate cancer, castration-resistant prostate cancer, drug therapy, treatment algorithms, clinical studies, etc. In accordance to foreign guidelines, it is essential to determine the high risk patients with non-metastatic CRPC and promptly apply new therapeutic options including apalutamide and enzalutamide, which have proven being effective in clinical trials as therapies that attenuate the transition of the non-metastatic CRPC to the metastatic stage. Foreign medical guidelines propose to apply a wider set of treatment algorithms for patients with metastatic CRPC, for instance: considerations on possibilities to use the cabazitaxel instead of docetaxel in the 1st line therapy in patients with pre-existing mild peripheral neuropathy, etc. as well as new therapies - pembrolizumab and sipuleucel-T. The issues regarding the selection of patients with CRPC for specific treatment algorithms and defining the optimal sequence of therapeutic regimens as well as combining various regimens with minimizing toxic effects and maximizing patient benefits remain unsolved.

Keywords

review / castration-resistant prostate cancer / clinical trials / therapeutic options / treatment algorithms / hormone therapy / chemotherapy

References

[1] Pernar C.H., Ebot E.M., Wilson K.M., Mucci L.A. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018. doi:10.1101/cshperspect.a030361

[2] Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018.

[3] Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018.

[4] Маркова А.С. Современные возможности лекарственного лечения кастрационно-резистентного рака предстательной железы. Онкоурология. 2013; 2: 73-7.

[5] Gallaher J., Cook L.M., Gupta S., Araujo A., Dhillon J., Park J.Y., et al. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin Exp Metastasis. 2014; 31(8): 991-9. doi:10.1007/ s10585-014-9674-1

[6] Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11): 1180-92. doi:10.1111/j.1742-1241.2011.02799.x

[7] Toren P.J., Gleave M.E. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl. 2013; 15(3): 342-9. doi:10.1038/aja.2013.38

[8] Моргенталер А. РПЖ: старая догма и новые трюки. Урология сегодня. 2013; 6. Доступно по адресу: http://urotoday.ru/ issue/6-2013/article/rpzh-testosteronovyi-paradoks

[9] NCCN Guidelines Version 4.2018. Prostate Cancer 2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate. pdf. 2018.

[10] Shore N., Mason M., de Reijke T.M. New developments in castrate-resistant prostate cancer. BJU Int. 2012; 109 Suppl 6: 22-32. doi:10.1111/j.1464-410X.2012.11217.x

[11] Smith M.R., Antonarakis E.S., Ryan C.J., Berry W.R., Shore N.D., Liu G. et al. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016; 70(6): 963-70. doi:10.1016/j.euru-ro.2016.04.023

[12] Smith M.R., Saad F., Chowdhury S., Oudard S., Hadaschik B.A., Graff J.N. et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15): 1408-18. doi:10.1056/NEJMoa1715546

[13] Penson D.F., Armstrong A.J., Concepcion R., Agarwal N., Olsson C., Karsh L. et al. Enzalutamide Versus Bicalutamide in CastrationResistant Prostate Cancer: The STRIVE Trial. J Clin Oncol. 2016; 34(18): 2098-106. doi:10.1200/JCO.2015.64.9285

[14] Hussain M., Fizazi K., Saad F., Rathenborg P., Shore N., Ferreira U. et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018; 378(26): 2465-74. doi:10.1056/ NEJMoa1800536

[15] Ryan C.J., Crawford E.D., Shore N.D., Underwood W., 3rd, Ta-plin M.E., Londhe A. et al. The IMAAGEN Study: Effect of Abi-raterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. J Urol. 2018; 200(2): 344-52. doi:10.1016/j.juro.2018.03.125

[16] Mateo J., Fizazi K., Gillessen S., Heidenreich A., Perez-Lopez R., Oyen WJG, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2018. doi:10.1016/j.eururo.2018.07.035

[17] Ernst D.S., Tannock IF., Winquist E.W., Venner P.M., Reyno L., Moore M.J. et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/pred-nisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003; 21(17): 3335-42. doi:10.1200/ JCO.2003.03.042

[18] Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15): 1502-12. doi:10.1056/NEJMoa040720

[19] Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N.Jr., Jones J.A., Taplin M.E. et al. Docetaxel and estramustine compared with mito-xantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15): 1513-20. doi:10.1056/NEJMoa041318

[20] Fizazi K., Scher H.I, Molina A., Logothetis C.J., Chi K.N., Jones R.J. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13(10): 983-92. doi:10.1016/S1470-2045(12)70379-0

[21] Shivji A., Ali R., North S., Sawyer M., Ghosh S., Chambers C. Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. J Oncol Pharm Pract. 2018:1078155218784716. doi:10.1177/1078155218784716

[22] Ryan C.J., Smith M.R., Fizazi K., Saad F., Mulders P.F., Sternberg C.N. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015; 16(2): 152-60. doi:10.1016/S1470-2045(14)71205-7

[23] Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13): 1187-97. doi:10.1056/ NEJMoa1207506

[24] Beer T.M., Armstrong A.J., Rathkopf D., Loriot Y., Sternberg C.N., Higano C.S. et al. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017;71(2):151-4. doi:10.1016/j.eururo.2016.07.032

[25] Oudard S., Fizazi K., Sengelov L., Daugaard G., Saad F., Hansen S. et al. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol. 2017; 35(28): 3189-97. doi:10.1200/JCO.2016.72.1068

[26] de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747): 1147-54. doi:10.1016/S0140-6736(10)61389-X

[27] Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5): 411-22. doi:10.1056/ NEJMoa1001294

[28] Package Insert. Keytruda (pembrolizumab). Whitehouse Station. NJ: Merck & Co, Inc.; 2017. 2017. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2017/125514s031lbl.pdf. 2018.

[29] Sartor O., Sharma D. Radium and other alpha emitters in prostate cancer. Transl Androl Urol. 2018; 7(3): 436-44. doi:10.21037/ tau.2018.02.07

[30] Parikh S., Murray L., Kenning L., Bottomley D., Din O., Dixit S. et al. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer. Clin Oncol (R Coll Radiol). 2018; 30(9): 548-55. doi:10.1016/j. clon.2018.06.004

[31] Bindal P., Jalil S.A., Holle L.M, Clement J.M. Potential role of rituximab in metastatic castrate-resistant prostate cancer. J Oncol Pharm Pract. 2018. 1078155218790338. doi:10.1177/1078155218790338

[32] Sobhani N., Generali D., D'Angelo A., Aieta M., Roviello G. Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. Invest New Drugs. 2018. doi:10.1007/s10637-018-0653-2

[33] Kim Y.J., Kim Y.I. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic CastrateResistant Prostate Cancer: A Meta-analysis. Clin Nucl Med. 2018. doi:10.1097/RLU.0000000000002210

[34] Gupta S., Nordquist L.T., Fleming M.T., Berry W.R., Zhang J., Ervin S.L. et al. Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018. doi:10.1158/1078-0432. CCR-18-0564

RIGHTS & PERMISSIONS

Eco-Vector